David S McKinsey, Joel P McKinsey, Julie R McKinsey, Maithe Enriquez
{"title":"Optimizing Missouri's Preparation for the Next Pandemic: Lessons Learned from COVID-19: Part 1.","authors":"David S McKinsey, Joel P McKinsey, Julie R McKinsey, Maithe Enriquez","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":74203,"journal":{"name":"Missouri medicine","volume":"121 6","pages":"424-432"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11651261/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142857174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Communication and Follow-Up of Noncritical Actionable Imaging Findings.","authors":"Govind Mattay, Andrew Bierhals","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":74203,"journal":{"name":"Missouri medicine","volume":"121 6","pages":"433-435"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11651264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142857137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Thwarting the Harm Caused by Private Equity in Surgical Practices … and Even in the NFL: <i>Part 2</i>.","authors":"Andrew Schlafly","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":74203,"journal":{"name":"Missouri medicine","volume":"121 6","pages":"419-423"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11651258/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142857199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The Global Initiative for Asthma (GINA) was established in 1993 and publishes a yearly global strategy to improve asthma awareness, prevention and management of asthma worldwide, based on a review of the most updated evidence. The current 2024 GINA update advises that all adults and adolescents with asthma receive inhaled corticosteroid (ICS)- containing medication and should not be treated with short acting beta agonist (SABA) alone. The 2024 GINA strategy divides treatment into two 'Tracks": Track 1 (preferred Track), the reliever is as-needed combination low dose ICS-formoterol; Track 2 uses SABA as the reliever along with a separate ICS inhaler. The updates also stress the importance that individuals with asthma should have a written asthma action plan, and asthma management should be tailored to the individual to help reduce the occurrence of serious exacerbations, fatalities, and hospitalizations.
{"title":"Update on Asthma Management Guidelines.","authors":"Sarah Dubin, Pooja Patak, Diana Jung","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The Global Initiative for Asthma (GINA) was established in 1993 and publishes a yearly global strategy to improve asthma awareness, prevention and management of asthma worldwide, based on a review of the most updated evidence. The current 2024 GINA update advises that all adults and adolescents with asthma receive inhaled corticosteroid (ICS)- containing medication and should not be treated with short acting beta agonist (SABA) alone. The 2024 GINA strategy divides treatment into two 'Tracks\": Track 1 (preferred Track), the reliever is as-needed combination low dose ICS-formoterol; Track 2 uses SABA as the reliever along with a separate ICS inhaler. The updates also stress the importance that individuals with asthma should have a written asthma action plan, and asthma management should be tailored to the individual to help reduce the occurrence of serious exacerbations, fatalities, and hospitalizations.</p>","PeriodicalId":74203,"journal":{"name":"Missouri medicine","volume":"121 5","pages":"364-367"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11482852/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142482474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Harm from Private Equity's Takeover of Medical Practices and Hospitals.","authors":"Andrew Schlafly","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":74203,"journal":{"name":"Missouri medicine","volume":"121 5","pages":"328-332"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11482842/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142482471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Obstructive sleep apnea (OSA) is a widespread sleep disorder characterized by repeated collapse of the upper airway during sleep, resulting in disruption of sleep. This condition is linked to a host of symptoms, including excessive daytime sleepiness, cardiovascular disorders, and a variety of other comorbidities. Continuous positive airway pressure (CPAP) is, by far, the most common treatment for OSA, and has long served as the standard treatment for most patients. However, CPAP therapy has a variety of limitations, including low adherence, and the heterogenous presentation of OSA. Thus, there exists an increasing need for alternative therapies for OSA. Some of these include lifestyle modifications, positional therapy, mandibular advancement devices, upper airway surgery, pharmacological therapies, and hypoglossal nerve stimulation. Because OSA presents heterogeneously, effective treatment for most patients would likely include a combination of these treatments.
阻塞性睡眠呼吸暂停（OSA）是一种广泛存在的睡眠障碍，其特点是睡眠时上气道反复塌陷，导致睡眠中断。这种疾病与一系列症状有关，包括白天过度嗜睡、心血管疾病和其他多种并发症。到目前为止，持续气道正压（CPAP）是治疗 OSA 最常见的方法，长期以来一直是大多数患者的标准治疗方法。然而，CPAP 治疗有很多局限性，包括依从性低，以及 OSA 的表现多种多样。因此，对 OSA 替代疗法的需求与日俱增。其中包括改变生活方式、体位疗法、下颌前突装置、上气道手术、药物疗法和舌下神经刺激疗法。由于 OSA 的表现不尽相同，因此对大多数患者的有效治疗可能包括这些疗法的组合。
{"title":"Non-CPAP Therapies for Obstructive Sleep Apnea in Adults.","authors":"Rayyan Abid, Lawrence Zhang, Abid Bhat","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Obstructive sleep apnea (OSA) is a widespread sleep disorder characterized by repeated collapse of the upper airway during sleep, resulting in disruption of sleep. This condition is linked to a host of symptoms, including excessive daytime sleepiness, cardiovascular disorders, and a variety of other comorbidities. Continuous positive airway pressure (CPAP) is, by far, the most common treatment for OSA, and has long served as the standard treatment for most patients. However, CPAP therapy has a variety of limitations, including low adherence, and the heterogenous presentation of OSA. Thus, there exists an increasing need for alternative therapies for OSA. Some of these include lifestyle modifications, positional therapy, mandibular advancement devices, upper airway surgery, pharmacological therapies, and hypoglossal nerve stimulation. Because OSA presents heterogeneously, effective treatment for most patients would likely include a combination of these treatments.</p>","PeriodicalId":74203,"journal":{"name":"Missouri medicine","volume":"121 5","pages":"385-390"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11482849/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142482468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号